Probiotic Composition for Improving Soy Protein Proteolysis and Amino Acid Production Activity
Summary
USPTO granted patent US12599641B2 to Lactomason Co., Ltd. on April 14, 2026. The patent covers a probiotic composition that improves soy protein proteolysis and branched-chain amino acid production to prevent sarcopenia. The mixed bacterial strain formulation demonstrates enhanced self-aggregation, hydrophobicity, and intestinal adhesion compared to single-strain alternatives.
What changed
USPTO granted patent US12599641B2 to Lactomason Co., Ltd. for a probiotic composition that enhances soy protein proteolysis and branched-chain amino acid production to prevent sarcopenia. The composition uses a mixed bacterial strain with improved self-aggregation, hydrophobicity, and intestinal adhesion properties compared to single strains.
This patent is relevant for manufacturers developing probiotic supplements, nutritional products, or therapeutic compositions targeting age-related muscle loss, protein metabolism, or antioxidant applications.
Archived snapshot
Apr 18, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Probiotic composition for improving soy protein proteolysis and amino acid production activity
Grant US12599641B2 Kind: B2 Apr 14, 2026
Assignee
LACTOMASON CO., LTD.
Inventors
Young Jin Lee, Woo Hyun Jung, So Lim Shin, Minn Sohn
Abstract
The present disclosure can improve the degree of soy protein proteolysis and the ability to produce valine, isoleucine, and leucine, which are branched-chain amino acids, as well as other amino acids, such as threonine, glycine, tyrosine, and lysine. Accordingly, the present disclosure can prevent sarcopenia and has antioxidant activity. Also, the present disclosure can maintain protein metabolic balance and relieve sarcopenia by muscle synthesis. The self-aggregation, hydrophobicity, and intestinal adhesion of a mixed strain is improved compared to a case where a single strain used for the mixed strain is used. Therefore, when the mixed strain of the present disclosure is ingested, the strain can remain for a long time in the intestine.
CPC Classifications
A61K 35/747 A61K 2035/115 A61P 1/14
Filing Date
2024-05-28
Application No.
18675254
Claims
14
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.